Member Info for HarChris

And yes I do think comments here can make a difference to a share price for a small cap stock on AIM. Not significantly no but to a small degree. And I also believe deep down you do too or there'd be no point spreading the sort of subtle negativity that you do across various bbs.

Neither did I say that you described BMN as such but you popped on here today to post six or seven negative comments.

I would say that it's an auspicious sign when the biggest bb detractors also think there's little downside.

'I think steady growth in production is probable, and I think there is
not much downside to the shares from this level.'

This just proves that you don't think BMN is worthless junk, overvalued or anything like that... you're trying to take advantage of negative sentiment to get in a bit lower.

Yes it would appear to me that the DHSC were left in the position of having to pay up or escalate the situation to a legal claim - the bad news for us is, despite what we thought with Nanopore's recent payout, we aren't likely to receive the money we are owed anytime soon/without a bit of a fight.

Besides that not much has changed with this rns but it sure is frustrating.

Most here are fully aware that 48p was a punchy valuation in 2018. This year we will be producing around 75% more vanadium than we did in 2018 and 100% more in 2023 vs 2018. When you factor in our 100% ownership of vanchem vs 74% of vametco those percentages increase further.

Since then we also have built a significant stake in a vrfb storage company (enerox) and are close to commissioning our very own electrolyte plant.

We may not have been truly worth 48p a share in 2018 but in time we will be.

As a 5400mtV vanadium producing company selling into a buoyant vanadium market strengthened by the new and growing vanadium redox flow battery sector I see BMN comfortably making $100m a year as things stand. There are a lot of factors that determine a share price but I see no reason why they can't command a valuation at least as high as $1b in the (not too distance) future.

I have an average of 11.5p here now with close to a million shares. If/when that holding is worth over half a million pounds I will consider that enormous returns. I believe that valuation is eminently achievable with minimal downside at today's price.

I have traded DDDD and Argo and made decent money. My main investment is BMN and I have full confidence in seeing enormous returns over the next 1-2 years.

I'd ignore Calamari - a) he doesn't understand the BMN business and b) I doubt he cares about investing the time to do so.

BMN are almost 100% going to be making a net profit this year. That profit will be somewhere between £25m and £75m. What sort of profit do you expect from a company valued at £130m?

Deal!

'It will literally drop 30-50% today. How are people still oblivious?'

Fancy a sportsman's bet PI100? If it finishes more than 30% down today (in your range) I'll never post on this bb again, if it finishes less than that you never post on here again? Must be agreed before the market opens in 5 minutes...

Well maybe do some research before you put your hard earned money into a share. The dispute has always been this amount more or less. This is from the full year results over a year ago:

'The dispute primarily relates to Q4 2020 revenue totalling £129.1m in respect of a specific product supplied to the NHS. '

Okay so the claim is a few million more but the same ballpark.

Yeah how dare you share all that info you have DRB. We should all be like PI100, all negativity and no facts.

See DRB's post below...

Sounds a lot worse than it is. This is priced in but of course will take a bit of a hit in the immediate term.

As I've repeated many times this company was valued around £10m pre covid when they had just £1.5m in cash/cash equivalents and £7m of debt - if they could command that sort multiple back then then obviously now with zero insolvency issues and all the R&D, expertise, IP etc accumulated over the past two years we are worth a good few times our cash now at least.

Completely agree as well as the DHSC agreeing on a contract at the height of the pandemic only to then renege on it a few months later. Without that second contract the share price would never have got anywhere close to £12 in 2020…

Many also still fail to realise that despite having an enviable balance sheet it’s no easy feat to go from a £12m revenue generating business to a £200m+ revenue generating business - it takes skilled management, strategy and time.

I thought the article on the whole was reasonable and a decent starting point for new investors but this line is a bit ridiculous 'The long-term prospects for the Novacyt share price do still appear to be tied firmly to Covid testing.'

Really? Short term sure but long term? Is it not obvious that novacyt chose to maximise the opportunity whilst it was there? Does the author think the strategy come Thursday is going to be all about covid and crossing our fingers for new variants? Well it's obviously not.

What's also omitted is the sheer size and significance of the DHSC dispute. We have £65m of outstanding invoices of goods we supplied to the DHSC which ncyt has confidently stated on numerous occasions that they believe they have strong grounds to assert its contractual rights - the huge payout to Nanopore recently should give us even more optimism on that front. Receiving a sum in that region would push our net asset value miles past today's market cap...

I'm sure most of you will turn your nose up at a motley fool article but this contributor is generally very risk averse and doesn't promote AIM small caps very often so this all in all is a fairly positive article considering:

https://www.fool.co.uk/2022/04/22/is-the-novacyt-lonncyt-share-price-now-a-screaming-buy/

So a few days ago @byp you said you bought another £10k, since it's fallen a good 10% and now you're telling others to wait for 145p - rollercoaster of emotions you are you poor thing!

Do you not think it's possible that this time around they are skirting around the rules a bit more? They saw what happened the first couple of times they reported the crossing of a threshold promptly, it basically priced them out of accumulating more. Seeing as entities flout the rules around timely reporting constantly I still think it's possible they are steadily accumulating only to find out in the next TR1 that they are on 8% or 9% or even higher.

Just you wait, PI100 or someone else will quickly remind us of the director buys in 2020 as proof that it means nothing...

Joking aside yes this is very different. The new board have been together for six months now, they've taken stock of the situation and decided that ~£2.20 is a steal, 65% below the LTIP baseline price. It's not hard to see why though is it? Even in the worst case scenario, let's say we soon discover that DA and the mgmt team are lacking the imagination, the capabilities necessary to maximise this opportunity and rapidly transform the company into a dynamic billion pound diagnostics business... well we're still a profitable enterprise with £100m in the coffers, possibly rising soon to £150m so how much are we likely to lose long term from here, from an mcap of £135m? Very little I would vouch.

Now take the opposite, now imagination everything starts to fall into place and DA quickly gets the market excited again. That we have made in roads in cancer detection, in POC testing, that we are forging a partnership with biosynex...

Well I've added 8k shares today, i'm more than happy with the price this retrace has offered up.